Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07668635

Cannabis Effects on Opioid Self-Administration

The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Opioid Use Disorder Cannabis Use Chemically-Induced Disorders Marijuana Abuse Mental Disorders Narcotic-Related Disorders Opioid-Related Disorders Substance-Related Disorders

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Kentucky Center on Drug and Alcohol Research

Lexington, Kentucky, 40508, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with moderate to severe opioid use disorder who experience opioid withdrawal
  • No allergies or adverse reactions to cannabis or opioids
  • Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks

Exclusion criteria

  • Individuals seeking treatment for opioid use disorder

Treatment and study plan

Cannabis

Drug

Cannabis is administered three times daily during the active cannabis treatment period.

Placebo cannabis

Drug

Matched placebo cannabis is administered three times daily during the placebo treatment period.

Intranasal Opioid Agonist

Drug

Intranasal opioid agonists are administered during sample and self-administration sessions

Oral Opioid Agonist

Drug

Oral opioid agonist maintenance doses are administered four times daily throughout study participation.

Primary outcomes

  1. Number of Opioid Self-Administration Trials Completed

    Time frame: Up to 6.5 Weeks

    Number of drug-choice trials completed for intranasal opioid agonists during self-administration sessions.

Study contacts

Contact information is provided by the study sponsor or research team.

Paul Nuzzo

CONTACT

[email protected]

859-323-0002

Sponsors and collaborators

Lead sponsor

Shanna Babalonis, PhD

Other

Registry information

Official study title

Impact of Cannabis on Opioid Self-Administration

Important dates

Study start
2026
Primary completion
2030
Study completion
2031
First posted
Jun 25, 2026
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.